1191 related articles for article (PubMed ID: 21740079)
1. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Deedwania PC; Huang GW
Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
ROCKET AF Study Investigators
Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
[TBL] [Abstract][Full Text] [Related]
4. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Yates SW
Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
7. Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.
Lam S
Cardiol Rev; 2013; 21(4):207-12. PubMed ID: 23535530
[TBL] [Abstract][Full Text] [Related]
8. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
Savelieva I; Bajpai A; Camm AJ
Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Stewart RA
Curr Opin Cardiol; 2011 Jul; 26(4):294-9. PubMed ID: 21537165
[TBL] [Abstract][Full Text] [Related]
10. [Risk stratification for thromboembolism and antithrombotic prophylaxis in atrial fibrillation].
Di Pasquale G; Riva L
G Ital Cardiol (Rome); 2012 Nov; 13(11 Suppl 1):11S-18S. PubMed ID: 23160015
[TBL] [Abstract][Full Text] [Related]
11. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
12. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
13. New frontiers for stroke prevention in atrial fibrillation.
Prasad V; Kaplan RM; Passman RS
Cerebrovasc Dis; 2012; 33(3):199-208. PubMed ID: 22261539
[TBL] [Abstract][Full Text] [Related]
14. [Atrial fibrillation and thromboembolic events prevention. State of the art].
Matteoli S; Trappolini M; Chillotti FM
Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapies for stroke prevention in atrial fibrillation.
Economides Muñoz C; Singh BN
Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
[TBL] [Abstract][Full Text] [Related]
16. Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation.
Lam YY; Ma TK; Yan BP
Int J Cardiol; 2011 Jul; 150(1):4-11. PubMed ID: 21112648
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Hughes PJ; Freeman MK
Consult Pharm; 2012 Jun; 27(6):445-52. PubMed ID: 22698551
[TBL] [Abstract][Full Text] [Related]
18. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
[TBL] [Abstract][Full Text] [Related]
19. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Galanis T; Merli GJ
Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
